- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07842601
Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation
This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms. The study will evaluate whether TMS improves depressive symptoms and reduces opioid craving. The study will also assess smoking behaviors, treatment acceptability, and any side effects related to TMS.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gopalkumar Rakesh, MD
- Phone Number: 8592576402
- Email: Gopalkumar.Rakesh@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- University of Kentucky
-
Contact:
- Gopalkumar Rakesh, MD
- Phone Number: 8592579402
- Email: Gopalkumar.Rakesh@uky.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-75 years of age
- Willing and able to provide informed consent
- Able to read and speak english
- Opioid use disorder, in remission for at least a month
- Diagnosis of major depressive disorder confirmed with the Mini-International Neuropsychiatric Interview (MINI, 7.02)
- Minimum score of 10 on the 17-item Hamilton Depression Rating Scale (HDRS-17)
- Opioid craving score of 5 or greater on a 0-10 scale
- Stabilized on sublingual or depot buprenorphine for at least 8 weeks
Exclusion Criteria:
- Seizure disorder
- any other acute medical or behavioral disorder that would preclude safe participation
- Pregnant, nursing or planning to become pregnant during the study
- Magnetic resonance imaging (MRI) contraindications, including ferrous retainers, intracranial implants, or claustrophobia
- Surgical procedure planned during the study period
- Any other medical condition that could compromise participant well-being
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Transcranial Magnetic Stimulation (TMS)
Participants will receive active transcranial magnetic stimulation (TMS) using intermittent theta burst stimulation (iTBS). |
Intermittent theta burst stimulation (iTBS) delivered over the left dorsolateral prefrontal cortex using a TMS coil. |
|
Sham Comparator: Sham Transcranial Magnetic Stimulation (TMS)
Participants will receive sham transcranial magnetic stimulation (TMS) using the same treatment procedure without a significant electric field induced around the brain. |
Sham Transcranial Magnetic Stimulation (TMS) delivered using the same procedure as active TMS without a significant electric field induced around the brain. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Depressive Symptom Severity
Time Frame: Baseline through Week 13
|
Change in depressive symptom severity as measured by the 17-item Hamilton Depression Rating Scale (HDRS-17) from baseline, comparing participants receiving transcranial magnetic stimulation (TMS) with those receiving Shame TMS. Higher scores indicate greater depressive symptom severity. The HDRS-17 ranges from 0-52. |
Baseline through Week 13
|
|
Change in Opioid Craving
Time Frame: Baseline through Week 13
|
Change in opioid craving as measured by the Opioid Craving Scale (OCS) from baseline, comparing participants receiving the TMS with those receiving sham TMS. The OCD consists of three items rated 0 to 10, with the total score calculated as the average of the three items. A higher score indicates greater opioid craving. |
Baseline through Week 13
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 118798
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.